Caroline Seymour

Managing Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com

Articles

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

March 14th 2025

All the data on the tumor-agnostic approvals of T-DXd and repotrectinib are featured in this article and it's downloadable PDF visual pages!

Investigators Focus on Reducing On-Target, Off-Tumor Toxicities With CAR T-Cell Therapy in Solid Tumors

March 14th 2025

Renier Brentjens, MD, PhD, details solid tumors his laboratory is investigating CAR T-cell therapy in and ways to mitigate on-target, off-tumor toxicities.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

March 13th 2025

A BLA has been accepted in China seeking the approval of tisotumab vedotin for metastatic cervical cancer that has progressed on or after systemic therapy.

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

March 13th 2025

177Lu rhPSMA-10.1 injection led to proportionally higher absorbed radiation doses in tumors vs healthy tissues in patients with mCRPC.

Investigators Are Making Headway Bringing CAR T-Cell Therapy to Solid Tumors

March 12th 2025

Renier Brentjens, MD, PhD, details 3 reasons it’s challenging to make CAR T-cell therapies applicable for solid tumors and ways to overcome the obstacles.

Acalabrutinib Plus Bendamustine and Rituximab Displays Long-Term Activity in Frontline and R/R MCL

March 11th 2025

Acalabrutinib plus BR showed OS and PFS efficacy with a tolerable safety profile with long-term follow-up in first-line and R/R MCL.

First-Line T-DXd ± Pertuzumab Yields Durable Responses in HER2+ Metastatic Breast Cancer

March 10th 2025

T-DXd with or without pertuzumab produced responses in first-line, HER2-positive metastatic breast cancer.

Dato-DXd Plus Durvalumab ± Carboplatin Delivers Antitumor Activity in Advanced NSCLC

March 10th 2025

Frontline treatment with datopotamab deruxtecan plus durvalumab with/without carboplatin proved active in advanced NSCLC without actionable alterations.

Novel Index Identifies Social Vulnerability Barriers to Cancer Clinical Trial Enrollment

March 10th 2025

Lower odds of enrollment in cancer clinical trials could be associated with education, transportation, and neighborhood resources.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer

March 9th 2025

Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options

March 7th 2025

Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

Elacestrant Improves PFS Irrespective of ESR1 VAF Level in ER+/HER2-Negative Breast Cancer

March 7th 2025

PFS was extended with elacestrant vs SOC in pretreated, ER-positive, HER2-negative breast cancer, regardless of the level of ESR1 variant allele fraction.

BTK Degraders May Be a Promising Approach in CLL/SLL for Patients With Disease Progression

March 6th 2025

Nirav N. Shah, MD, MSHP, and Michael T. Tees, MD, MPH, detail BTK degraders such as NX-5948 under investigation in the CLL/SLL space.

Nogapendekin Alfa Inbakicept/CAR-NK Wins FDA RMAT Designation for Lymphopenia Reversal in Metastatic Pancreatic Cancer

March 5th 2025

The FDA granted RMAT designation to nogapendekin alfa inbakicept/CAR-NK for lymphopenia reversal in patients with advanced or metastatic pancreatic cancer.

Norway Grants Marketing Authorization to Illuccix PSMA-PET Imaging Agent in Prostate Cancer

March 5th 2025

NOMA has approved the PET imaging agent for the identification of PSMA-positive lesions in patients with prostate cancer.

Tumor-Agnostic Approvals of T-DXd and Repotrectinib Carry the Field Forward

March 5th 2025

Clinicians parse through the impacts of tumor-agnostic FDA approvals, examining T-DXd and repotrectinib's 2024 approvals in particular.

ARX788 Displays Activity in HER2+ Advanced Breast Cancer

March 5th 2025

ARX788 was safe and effective in HER2+ advanced breast cancer after disease progression on 1 line of a trastuzumab-based regimen.

Tivozanib Preserves QOL From Baseline to Week 24 in ICI-Pretreated RCC

March 4th 2025

Katy Beckermann, MD, PhD, discusses key findings from a PRO analysis of tivozanib/nivolumab vs tivozanib alone in ICI-pretreated RCC.

Quizartinib Plus Chemotherapy Is Set to Be Evaluated in FLT3-ITD-Negative AML in Phase 3 Trial

March 3rd 2025

Quizartinib with 7+3 chemotherapy was safe and effective in patients with FLT3-ITD–negative AML, leading to the initiation of the phase 3 QuANTUM-Wild trial.